In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

doi:10.1038/nature23270

. 2017 Jul 27;547(7664):413-418.

doi: 10.1038/nature23270. Epub 2017 Jul 19.

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Robert T Manguso^{1

2

3}, Hans W Pope^{1

3}, Margaret D Zimmer^{1

3}, Flavian D Brown^{1

2}, Kathleen B Yates^{1

3}, Brian C Miller^{1

3

4}, Natalie B Collins^{1

3

5}, Kevin Bi^{1

3}, Martin W LaFleur^{1

2}, Vikram R Juneja⁶, Sarah A Weiss¹, Jennifer Lo⁷, David E Fisher⁷, Diana Miao^{2

3}, Eliezer Van Allen^{2

3}, David E Root³, Arlene H Sharpe^{5

8}, John G Doench³, W Nicholas Haining^{1

3

5}

Affiliations

¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
² Division of Medical Sciences, Harvard Medical School, Boston, Massachusetts 02115, USA.
³ Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
⁵ Division of Pediatric Hematology and Oncology, Children's Hospital, Boston, Massachusetts 02115, USA.
⁶ Department of Microbiology and Immunology, Harvard Medical School, Boston, Massachusetts 02115, USA.
⁷ Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Building 149, 13th Street, Charlestown, Massachusetts 02129, USA.
⁸ Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, Massachusetts 02115, USA.

PMID: 28723893
PMCID: PMC5924693
DOI: 10.1038/nature23270

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Robert T Manguso et al. Nature. 2017.

. 2017 Jul 27;547(7664):413-418.

doi: 10.1038/nature23270. Epub 2017 Jul 19.

Authors

Affiliations

¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
² Division of Medical Sciences, Harvard Medical School, Boston, Massachusetts 02115, USA.
³ Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
⁵ Division of Pediatric Hematology and Oncology, Children's Hospital, Boston, Massachusetts 02115, USA.
⁶ Department of Microbiology and Immunology, Harvard Medical School, Boston, Massachusetts 02115, USA.
⁷ Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Building 149, 13th Street, Charlestown, Massachusetts 02129, USA.
⁸ Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, Massachusetts 02115, USA.

PMID: 28723893
PMCID: PMC5924693
DOI: 10.1038/nature23270

Abstract

Immunotherapy with PD-1 checkpoint blockade is effective in only a minority of patients with cancer, suggesting that additional treatment strategies are needed. Here we use a pooled in vivo genetic screening approach using CRISPR-Cas9 genome editing in transplantable tumours in mice treated with immunotherapy to discover previously undescribed immunotherapy targets. We tested 2,368 genes expressed by melanoma cells to identify those that synergize with or cause resistance to checkpoint blockade. We recovered the known immune evasion molecules PD-L1 and CD47, and confirmed that defects in interferon-γ signalling caused resistance to immunotherapy. Tumours were sensitized to immunotherapy by deletion of genes involved in several diverse pathways, including NF-κB signalling, antigen presentation and the unfolded protein response. In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon-γ-mediated effects on antigen presentation and growth suppression. In vivo genetic screens in tumour models can identify new immunotherapy targets in unanticipated pathways.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

**Extended Data Figure 1. Analysis of screen performance**
a, Western blot of for Cas9 and β-actin B16 cell lysate of uninfected cells or after transduction with a lentiviral vector encoding Cas9. For western blot source data, see Supplementary Fig. 1. b, Pie chart showing the fraction of genes targeted in the screen in each of the GO term categories indicated. c, Tumour volume for individual animals (dots) on the day of euthanasia in the conditions indicated. Data are mean ± s.d. d, 2D frequency histograms showing the pair wise distribution of sgRNAs abundance (averaged for each condition). e, Saturation analysis of animal replicates from the three *in vivo* screening conditions. Pearson’s correlations are calculated for the library distribution in one animal versus any other animal, then for two animals averaged versus any other two averaged, and so on. Saturation approaches r = 0.95. f, A matrix of the Pearson’s correlations of the library distribution from one animal compared to any other animal for B16 pool 1. g, Expression of PD-L1 (top) or CD47 (bottom) after infection of B16-Cas9 cells with four different sgRNAs targeting the indicated gene. h, Enrichment analysis (hypergeometric test) of functional classes of genes (GO) targeted by sgRNAs that were enriched or depleted in tumours in animals treated with GVAX and anti-PD-1 compared to *Tcra*^−/− animals. **P <0.01; ***P< 0.001; ****P< 0.0001.

**Extended Data Figure 2. Additional validation data for screen hits**
a, Expression of CD47 by B16 cells transfected with either CD47-targeting (red) or control (grey) sgRNA. b, Tumour volume over time for CD47− null or control tumours growing in mice treated with GVAX and PD-1 blockade. Data are mean ± s.e.m.; n = 10 animals per group; representative of two independent experiments. c, Tumour growth in immunotherapy-treated animals challenged with B16 cells lacking the indicated genes. Each line represents one animal; n = 5 animals per group. d, Tumour volume averaged for each group at each time point (left) and survival (right) for *Braf/Pten* melanoma cells lacking the indicated gene in mice treated with PD-1 blockade. Data are mean ± s.e.m.; n = 5 animals per group. e, Change in the ratios (log₂(normalized fold change)) of B16 cells lacking the indicated genes:control cells after *in vitro* culture with the combinations of cytokines indicated below. Data are mean ± s.e.m.; n = 3 replicates per group. f, Expression of MHC-I (H2K(b)/H2D(b)) on B16 cells lacking the indicated genes with or without IFNγ treatment. g, Change in the ratios (log₂(normalized fold change)) of OVA-expressing B16 cells lacking the indicated genes:control cells after *in vitro* co-culture with OVA-specific T cells at the indicated ratio of T cells:tumour cells. Data are mean ± s.d.; n = 3 replicates per group. *P < 0.05; **P< 0.01; ***P < 0.001; ****P < 0.0001.

Extended Data Figure 3. Additional validation data for *Ptpn2*
a, Western blot of B16 cell lysate for PTPN2 and β-actin after transfection with either control or *Ptpn2*-targeting sgRNAs. For western blot source data, see Supplementary Fig. 1. b, *Ptpn2* transcript abundance for the same conditions as in a measured by qPOR. Data are mean ± s.d. c, Change in the ratios (log₂(normalized fold change)) of B16 cells lacking *Ptpn2*:control cells in immunotherapy-treated mice relative to *Tcra*^−/− mice with three different sgRNAs. Data are mean ± s.d.; n = 5 animals per group; representative of two independent experiments. d, Survival analysis for *Ptpn2*-null (red) or control (grey) B16 cells growing in mice treated with GVAX and PD-1 blockade. n = 20 animals per group; representative of two independent experiments. **P <0.01; ****p< 0.0001.

**Extended Data Figure 4. Deletion of screen hits from tumour cells**
a, Western blot of B16 cell lysate for STAT1 (left) and JAK1 (right) after transfection with the indicated sgRNA and Cas9. β-Actin serves as a loading control for each. The numbers below the lane indicate the per cent expression of the target relative to control sgRNA cells. b, The same as in a, but for *Braf/Pten* melanoma cells. c, Expression of *Ifngr1* in B16 cells transfected with the indicated *Ifngr1*-targeting (red) or control (grey) sgRNA and Cas9 (left) and quantification of mean fluorescence intensity (right). d, The same as in c, but for *Braf/Pten* melanoma cells. e, Expression of *Ifnar2* in B16 cells transfected with the indicated *Ifnar2*-targeting or control sgRNA and Cas9 (left) and quantification of mean fluorescence intensity (right). f, Western blot of *Braf/Pten* melanoma cell lysate for PTPN2 and β-actin after transfection with either control or *Ptpn2*-targeting sgRNAs (left) and *Ptpn2* transcript abundance for the same conditions measured by qPCR (right). Data are mean ± s.d. g, Expression of *H2-T23* by B16-Cas9 cells infected with the indicated H2-T23-targeting (red) and control (grey) sgRNA. For western blot source data, see Supplementary Fig. 1. **P < 0.01.

Extended Data Figure 5. *Ptpn2-null* tumour cells do not have a growth disadvantage *in vivo* in the absence of T cells or immunotherapy and MC38 colon carcinoma cells are sensitive to *Ptpn2* deletion *in vivo*
a, Tumour volume averaged for each group at each time point for *Ptpn2*-null (red) or control (grey) B16 cells growing in wild-type (WT) mice with no treatment. Data are mean ± s.e.m.; n = 10 animals per group. b, Survival analysis for the groups shown in a. c, Tumour volume averaged for each group at each time point for *Ptpn2-null* or control B16 cells growing in *Tcra*^−/− mice with no treatment. Data are mean ± s.e.m.; n = 10 animals per group. d, Survival analysis for the groups shown in c. Both groups reached the end point on the same day. e, Tumour volume averaged for each group at each time point for *Ptpn2-null* or control *Braf/Pten* melanoma cells growing in *Tcra*^−/− mice with no treatment. Data are mean ± s.e.m.; n = 5 animals per group. f, Survival analysis for the groups shown in e. g, Tumour volume averaged for each group at each time point for *Ptpn2-null* or control MC38 cells growing in wild-type mice with no treatment. Data are mean ± s.e.m.; n = 10 animals per group. h, Survival analysis for the groups shown in g. i, Tumour volume averaged for each group at each time point for *Ptpn2-null* or control MC38 cells growing in *Tcra*^−/− mice with no treatment. Data are mean ± s.e.m.; n = 5 animals per group. j, Survival analysis for the groups shown in i. Both groups reached the end point on the same day. *P < 0.05.

**Extended Data Figure 6. Analysis of *Ptpn2* amplifications in human cancer using exome sequencing**
a, Patients treated with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapies in four cancer types: bladder cancer, head and neck squamous cell carcinoma (HNSCC), lung cancer and melanoma with copy-number amplifications (CNA) of *PTPN2* were grouped according to whether or not they received clinical benefit from immunotherapy. The mutational burden is indicated on the y axis and the type of amplification event (focal, arm level or chromosome level) is indicated for each patient.

**Extended Data Figure 7. *Ptpn2-null* tumours have increased effector T cell populations, but no other significant differences in immune infiltrates compared with control tumours were found**
a, Representative plots showing the gating strategy for the data shown in Fig. 4a. Populations of interest are gated in blue. b, The number of CD45⁺ cells per mg of tumour for *Ptpn2-null* (red) and control (grey) B16 tumours. Data are mean ± s.d. c, Representative plots showing the gating strategy for the quantification of T cell populations from *Ptpn2*-null and control B16 tumours shown in d. Populations of interest are gated in blue. d, Quantification of effector T cell populations in either *Ptpn2*-null or control B16 tumours. Data mean ± s.d. Data pooled from two independent experiments with a minimum of eight mice per group.

**Extended Data Figure 8. *Ptpn2-null* tumours show no significant differences in myeloid cell infiltration compared to control tumours**
a, Representative plots showing the gating strategy for the myeloid cell populations quantified in b. Populations of interest are gated in blue. b, Numbers of myeloid cells per mg of tumour for *Ptpn2-null* (red) and control (grey) B16 tumours. Data are mean s.d. Data pooled from two independent experiments with a minimum of eight mice per group.

**Extended Data Figure 9. *Ptpn2-null* tumour cells have increased MHC-I expression after IFNγ stimulation and have increased sensitivity to costimulation with TNF and IFNγ**
a, Expression of MHC-I (H2K(b)/H2D(b)) on either *Ptpn2-null* (red) or control (grey) B16 cells after stimulation with IFNγ for 72 h (left) and quantification of mean fluorescence intensity (right). Data are mean ± s.d. b, Gene set enrichment analysis showing enrichment of signatures for IFNγ, IFNα and TNFα signalling via NF-κB in *Ptpn2-null* B16 cells after costimulation with TNF and IFNγ relative to *Ptpn2-null* cells stimulated with IFNγ alone.

**Figure 1. *In vivo* CRISPR–Cas9 screening recovers known mediators of immune evasion and resistance**
a, Diagram of screening system. b, Tumour volume averaged for groups indicated. n = 40 per group. c, Frequency histograms of enrichment or depletion (z score) for all sgRNAs. sgRNAs targeting indicated genes are shown by the red lines. d, Depletion of CD47-targeting sgRNAs. e, Enrichment of IFNγ pathway sgRNAs. f, Diagram of *in vivo* competition assay. g, Ratio of control:control and control:*Stat1*-null B16 cells for conditions indicated. h, Change in the ratios of B16 cells lacking the indicated genes in immunotherapy-treated mice compared with *Tcra*^−/− mice. Data are mean ± s.e.m.; n = 8–10 mice per group). **P < 0.01; ***P < 0.001.

**Figure 2. Loss-of-function screening identifies targets that increase the efficacy of immunotherapy**
a, Frequency histograms of enrichment or depletion of sgRNAs targeting genes indicated. b, Competition assays of tumour cells lacking *Ptpn2, H2-T23, Ripk1* or *Stub1.* c, Ratios of tumour cells lacking the indicated genes. n = 3–13 mice per group; representative of two independent experiments. d, e, Tumour volume (d) and survival analysis (e) of *H2-T23-null* (red) or control (grey) B16 tumours. Data are mean ± s.e.m.; n = 10 mice per group; representative of two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

**Figure 3. Deletion of *Ptpn2* sensitizes tumours to immunotherapy**
**a, b**, Tumour volume for control tumours or those with gene deletions as indicated in B16 melanoma (a; n = 20 animals per group; representative of three independent experiments) and *Braf/Pten* melanoma (b; n = 10 animals per group; representative of two independent experiments; data are mean ± s.e.m.). c, d, Flow plots (c) and change in ratios (d) of *Ptpn2*-null, *Ptpn2* rescued or overexpressing B16 cells relative to control B16 cells. n = 5 animals per group. Data are mean ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001.

**Figure 4. Deletion of *Ptpn2* improves antigen presentation and T cell stimulation**
a, Quantification of immune cells in *Ptpn2*-null (red) or control (grey) B16 tumours. n = 8-10 animals per group; data from two experiments. b, Immunohistochemistry for CD8α in control or *Ptpn2*-null tumours. n = 4-5 animals per group. c, Granzyme B (Gzmb) expression by CD8⁺ T cells in *Ptpn2*-null or control B16 tumours. n = 8-10 animals per group; data from two experiments. d, SIINFEKL-H2K(b) presentation by *Ptpn2*-null or control B16 cells. MFI, mean fluorescence intensity. e, Intracellular IFNγ and TNF staining in CD8+ T cells after restimulation with *Ptpn2*-null or control B16 cells. f, Ratios of B16 cells lacking the indicated genes after co-culture with antigen-specific T cells. n = 3; representative of two independent experiments. Data are mean ± s.d. *P <0.05; **P< 0.01; ***P< 0.001.

**Figure 5. Deletion of *Ptpn2* sensitizes tumours to IFNγ**
a, p-STAT1 after IFNγ treatment of control, *Ptpn2*-null, rescued or overexpressing (OX) B16 cells. For western blot source data, see Supplementary Fig. 1. b, IFNγ response gene expression in *Ptpn2*-null or control B16 cells. c, Gene set enrichment analysis of IFNγ response genes in mouse and human tumour cell lines. d, e, Ratios of mouse (d) or human (e) tumour cells with the indicated sgRNA cultured with the indicated cytokines. n = 3 replicates; representative of two independent experiments. Data are mean ± s.d. f, Diagram of the type I and type II interferon pathway. g, Flow cytometry plots showing frequencies of *Stat1/Ptpn2* double-null cells versus *Stat1*-null cells (right) and *Ptpn2*-null cells versus control cells (left) in the condition indicated. n = 5 mice per group. h, Change in ratio of *Stat1/Ptpn2* double-null cells versus *Stat1*-null cells and *Ptpn2*-null cells versus control cells in the condition indicated. **P < 0.01; ***P < 0.001; NS, not significant.

See this image and copyright information in PMC

Republished in

Immunotherapy: Searching in the immune checkpoint black box.
Villanueva MT. Villanueva MT. Nat Rev Cancer. 2017 Sep;17(9):511. doi: 10.1038/nrc.2017.75. Epub 2017 Aug 24. Nat Rev Cancer. 2017. PMID: 28835721 No abstract available.

Comment in

Cancer immunotherapy: Searching in the immune checkpoint black box.
Villanueva MT. Villanueva MT. Nat Rev Drug Discov. 2017 Sep;16(9):599. doi: 10.1038/nrd.2017.163. Epub 2017 Aug 11. Nat Rev Drug Discov. 2017. PMID: 28799544 No abstract available.
PTPN2: a tumor suppressor you want deleted?
Wiede F, Tiganis T. Wiede F, et al. Immunol Cell Biol. 2017 Nov;95(10):859-861. doi: 10.1038/icb.2017.70. Epub 2017 Oct 10. Immunol Cell Biol. 2017. PMID: 28994418 No abstract available.
CRISPR takes genetic screens forward.
Neff EP. Neff EP. Lab Anim (NY). 2020 Jan;49(1):13-16. doi: 10.1038/s41684-019-0445-0. Lab Anim (NY). 2020. PMID: 31853027 No abstract available.

Cited by

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellm… See abstract for full author list ➔ Skoulidis F, et al. Nature. 2024 Oct 9. doi: 10.1038/s41586-024-07943-7. Online ahead of print. Nature. 2024. PMID: 39385035
Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma.
Li HY, Jing YM, Shen X, Tang MY, Shen HH, Li XW, Wang ZS, Su F. Li HY, et al. World J Gastrointest Oncol. 2024 Sep 15;16(9):3913-3931. doi: 10.4251/wjgo.v16.i9.3913. World J Gastrointest Oncol. 2024. PMID: 39350977 Free PMC article.
In vivo CRISPR screens identify Mga as an immunotherapy target in triple-negative breast cancer.
Feng X, Yang C, Huang Y, Su D, Wang C, Wilson LL, Yin L, Tang M, Li S, Chen Z, Zhu D, Wang S, Zhang S, Zhang J, Zhang H, Nie L, Huang M, Park JI, Hart T, Jiang D, Jiang K, Chen J. Feng X, et al. Proc Natl Acad Sci U S A. 2024 Sep 24;121(39):e2406325121. doi: 10.1073/pnas.2406325121. Epub 2024 Sep 19. Proc Natl Acad Sci U S A. 2024. PMID: 39298484
Mechanism of TBK1 activation in cancer cells.
Hu L, Zhang Q. Hu L, et al. Cell Insight. 2024 Aug 22;3(5):100197. doi: 10.1016/j.cellin.2024.100197. eCollection 2024 Oct. Cell Insight. 2024. PMID: 39279883 Free PMC article. Review.
Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy.
Liu Y, Xu C, Zhang L, Xu G, Yang Z, Xiang L, Jiao K, Chen Z, Zhang X, Liu Y. Liu Y, et al. Sci Adv. 2024 Sep 13;10(37):eadi7764. doi: 10.1126/sciadv.adi7764. Epub 2024 Sep 11. Sci Adv. 2024. PMID: 39259785 Free PMC article.

See all "Cited by" articles

References

1. Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833. - PubMed
1. Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133. - PMC - PubMed
1. Zaretsky JM, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–829. - PMC - PubMed
1. Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800. - PubMed
1. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison J. P Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210:1389–1402. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
Molecular Biology Databases
- Guide to Pharmacology
Research Materials
- Addgene Non-profit plasmid repository
- NCI CPTC Antibody Characterization Program

[1] Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833. - PubMed

[2] Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833. - PubMed

[3] Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133. - PMC - PubMed

[4] Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133. - PMC - PubMed

[5] Zaretsky JM, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–829. - PMC - PubMed

[6] Zaretsky JM, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–829. - PMC - PubMed

[7] Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800. - PubMed

[8] Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800. - PubMed

[9] Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison J. P Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210:1389–1402. - PMC - PubMed

[10] Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison J. P Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210:1389–1402. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Affiliations

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Republished in

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Research Materials

Abstract

Conflict of interest statement

Figures

Republished in

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Research Materials